BIT's 10th Annual International Congress of Antibodies (ICA-2018)
Highlights

● Designing 100+ Sessions of Scientific Forums, Symposia, Roundtables, Dialogs, Workshops, And Training Courses Covering Top Trends and Advances in Biotherapeutic R & D
● Inviting Worldwide Distinguished Experts, Investors, And Decision Makers in the Areas of Protein R & D for the Grand Thought Collision from 50+ Countries
● Shooting for 500+ Oral Presentations and Hot Paper Briefing in Whole Spectrum of Breakthroughs in Biopharmaceutical R & D from both Industry and Academia
● Gathering 50+ Exhibitors in Cutting-Edge Technologies and Novel Bioproducts
● Bring in up to 1000 Distinguished Participants All Together in Fields of Immunotherapy, such as Antibody and Vaccines, Gene Therapy, Cell Therapy and protein therapeutics to Knowledge Mall, Miami
● Bringing in 10+ Professional Media Supporters
● Scheduling 4+ Sessions of Business & Career Development, And Talent Search
● Multi-Zones of Poster Show and Exhibitions of New Finding, New IP, New Tech and New Products
● 2-3 Interactive Events to Enhance the Professional Network and Matchmaking
●One Annual Report Release/Peers Review on Current Trend, Economic Value, Scientific Breakthroughs and Future Directions on Biotherapeutic R & D

Confirmed Keynote Speakers
说明: 3359825024 Dr. Sanjaya Singh
Global Head, Janssen Research & Development, Janssen BioTherapeutics, Johnson & Johnson , USA

Dr. Thomas J. Webster

Art Zafirpoulo Chair, Chair Department of Chemical Engineering, Northeastern University, USA

Dr. Sanjaya Singh
Sanjaya Singh, Ph.D., is Global Head, Janssen BioTherapeutics within Janssen Research & Development. Sanjaya is responsible for leading an organization focused on biotherapeutic research, discovery, toxicology, clinical pharmacology and strategic external collaboration. In this role, Sanjaya drives the strategy and overall vision to expand and apply the capabilities of Janssen Research & Development to the discovery and development of protein, peptide and cell-based therapeutics.
Sanjaya is an accomplished scientific and business leader with more than 25 years of industry and academic experience. Prior to joining Johnson & Johnson, Sanjaya spent nine years at Boehringer Ingelheim, most recently serving as Vice President, Biotherapeutics Discovery. During his tenure, Sanjaya led a global team responsible for building a competitive and productive pre-clinical and clinical biotherapeutics pipeline. He has successfully led the identification of therapeutic targets in the field of immunomodulation and has developed biologic molecules in the fields of immunology, oncology, ophthalmology, cardio-metabolic and infectious disease.
In the realm of academia, Sanjaya held a faculty position in the Department of Molecular Biology at the Institute of Life Sciences in India. An author of numerous peer-reviewed articles, Sanjaya also is co-author on more than 25 patents.
Sanjaya earned a Ph.D. in Molecular Biology from Banaras Hindu University, Varanasi, Uttar Pradesh, India. He served as a Postdoctoral Fellow in the Department of Molecular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, and as a Research Associate in the Department of Biochemistry and Molecular Biology, also at MD Anderson Cancer Center in Texas.


Dr. Thomas J. Webster
Thomas J. Webster (H index: 82) is the Chemical Engineering Department Char and Art Zafiropoulo Endowed Chair at Northeastern University in Boston. Prof. Webster has graduated 144 students. His lab group published 9 textbooks, 48 book chapters, 403 articles, and 32 provisional/full patents. Prof. Webster has received numerous honors: 2012, Fellow, American Institute for Medical and Biological Engineering; 2013, Fellow, Biomedical Engineering Society; 2015, Wenzhou 580 Award; 2015, Zheijang 1000 Talent Program; 2016, IMRC Chinese Academy of Science Lee-Hsun Lecture Award; 2016, Fellow, Biomaterials Science and Engineering; 2016, Acta Biomaterialia Silver Award; and 2017, Fellow, National Academy of Inventors. He has started over 12 companies with several FDA approved medical devices based on nanomedicine. He also frequently appears on the BBC, NBC, ABC, Fox, National Geographic, Discovery Channel and many other news outlets talking about science.

Program Layout

Please click on the subjects under preliminary program to learn more about speaker’s profile and their presentations. Time arrangement is subject to change without notice. Please take the final program as the standard.


BIT’s 2nd Annual International Congress of Biotherapy
Path 1:  Main Conference
-Vision from the World Leaders in Combating Major Diseases
Path 2: Biodiscovery Harbor
-Advances in Preclinical Research of Biotherapy
Path 3: Industrial Innovator’s Hub
-Next Big Things in Biopharma Development
Path 4: Fastest Growing Enterprise Nexus
-New Champions in Emerging Biopharmaceutical Industry
Path 5: Mind Lab
-Your Career and Your Business
Path 6: Silkroad Partnership Post
-What R & B Can Offer New Opportunities for Biopharma World
Path 7: Biotherapeutic Bazaar
-Posters and Exhibits
Path 8: Joyful Commune
-Sharing the Diversities for Common Interests
Special Events
- Anniversary of BIT’s Twin conferences in Antibody and Vaccine

BIT’s 10th Anniversary of International Congress of Antibody
Joint-Keynote Forum with WCV-2018
Stream 1: Global Update on Antibodies Market Trends and Industry Strategies Stream 2: Next-Generation Antibodies
Stream 3: Antibodies for Cancer Therapy Stream 4: New Antibodies for Other Major Diseases
Stream 5: New Achievements in Antibody Research Stream 6: Antibody Engineering and Production

BIT’s 11th Anniversary of World Congress of Vaccines
Joint-Keynote Forum with ICA-2018
-Outlook of Global Immunotherapy, Vaccination and Immunization
Theme 1: Global Vaccination/Immunization Action Plan, and Partnership
- Strategy, Policy, Market Trends, Challenges and Opportunities
Theme 2: Art and Technologies in Vaccine Development
-Creativity, Innovation and Productivity
Theme 3: Innovative Human Vaccines-Infectious Diseases
-Combating Emerging and Re-emerging Pandemics
Theme 4: Innovative Human Vaccines-Non-Infectious Diseases
-Bio-ways in Hackling Unmet Medical Demands to Save Lives
Theme 5: Cancer Vaccines
-Moonshot for Final Solutions to Cancer Treatment
Theme 6: Veterinary Vaccines
-Securing One Health Biosphere
Theme 7: Vaccine Bioprocessing
-Green Growth in Vaccine Development
Past Renowned Speakers
说明: http://www.bitcongress.com/uploadfile/2016090610433873499.bmp Dr. Weikang Tao, Vice President and CEO of R&D Center, Jiangsu Henrui Medicine Co., Ltd., China 说明: http://www.bitcongress.com/uploadfile/2016070708590573499.bmp Dr. Madi Madiyalakan, CEO, Quest PharmaTech Inc., Canada 说明: http://www.bitcongress.com/uploadfile/2017021013335973499.jpg Dr. Dan Zhang, Chairman and CEO, Fountain Medical Development Ltd. China
Dr. Patrick Liu, Vice President, Teva Pharmaceuticals Ltd., USA Dr. Jose de Chastonay, Chief Marketing Officer, Bachem Holding AG, Switzerland Dr. Vadim T. Ivanov, Professor, Director, Russian Academy of Sciences, Russia
Dr. Priyabrata Pattnaik, Director of Worldwide Vaccine Initiative, Merck, Singapore 说明: http://www.bitcongress.com/ica2015/images/ks/ks_1.jpg Dr. Andrew Wang, Chairman, Taiwan Antibody Association, Taiwan 说明: http://www.bitcongress.com/ica2015/images/ks/ks_2.jpg Dr. Liangzhi Xie, Founder & CEO, Sino Biological Inc., China
说明: http://www.bitcongress.com/ica2015/images/ks/ks_3.jpg Dr. Dimiter S Dimitrov, Head, National Cancer Institute, USA 说明: http://www.bitcongress.com/ica2015/images/ks/ks_4.jpg Dr. Chien-Hsing Ken Chang, Vice President, Research and Development, Immunomedics, Inc., USA 说明: http://www.bitcongress.com/ica2015/images/ks/ks_5.jpg Dr. Michael Yu, Presidert, Innovent Biologics, Inc., China
Dr. Paul Chapman, Head of Biopharm Process Solutions, EMD Millipore, USA Dr. Scott P Carmer, Chief Operating Officer, NexImmune Inc., USA Dr. Peter A. Ward, Stobbe Professor of Pathology, University of Michigan Health Systems, USA
Exhibition and Sponsorship

ICB-2018 & ICA-2018 & WCV-2018 provides an ideal platform to showcase your new technologies and products in Miami, USA. It is developed to maximize your exposure, generate new leads, build brand awareness, and solidify business relations.
More>>

ICB-2018 & ICA-2018 & WCV-2018 is one of the most effective international marketing platforms in the field of Biotherapy, Antibody and Vaccine, which offers a wide range of sponsoring categories for branding and highlighting your company in order to achieve the best publicity.
More>>

Company List
News Updates
Executive Co-Chair

John Xu
MD, MBA, MS Sr.
SVP of Strategic Alliance, USA
Brochure
Hosting Organization
Supporting Organizations
Official Travel Agency
BIT's Upcoming Events
©2016-2017 All rights reserved by BIT Congress Inc.
Contact Us: Tel: 0086-411-84799609, Fax: 0086-411-84796897